Skip directly to page options Skip directly to A-Z link
Volume 18, Number 11—November 2012
Research

HIV Infection and Geographically Bound Transmission of Drug-Resistant Tuberculosis, Argentina

Viviana RitaccoComments to Author , Beatriz López, Marta Ambroggi, Domingo Palmero, Bernardo Salvadores, Elida Gravina, Eduardo Mazzeo, Susana Imaz, Lucía Barrera, and National TB Laboratory Network
Author affiliations: Instituto Nacional de Enfermedades Infecciosas ANLIS “Dr. Carlos G. Malbrán,” Buenos Aires, Argentina (V. Ritacco, B. López, E. Mazzeo, L. Barrera); Hospital “Dr. F.J. Muñiz,” Buenos Aires (M. Ambroggi, D. Palmero); Programa Provincial de Tuberculosis, Santa Fe, Argentina (B. Salvadores); Hospital Zonal General Agudos “Dr. Diego Paroissien,” La Matanza, Argentina (E. Gravina); and Instituto Nacional de Enfermedades Respiratorias “Dr. Emilio Coni” ANLIS “Dr Carlos G Malbran,” Santa Fe (S. Imaz)

Main Article

Table 3

Putative risk factors for case-patients with newly diagnosed multidrug-resistant TB in 7 major genotype clusters, Argentina 2003–2009

Cluster
(SIT)* Area Total no. case-patients Risk factor, no. (%) case-patients
Previously treated for TB HIV positive HCWs Other hospital exposure† Prison Household
exposure Unknown
M H2 (2) Buenos Aries 228 78 (34.2) 116 (50.9) 21 (9.2) 38 (16.7) 23 (10.1) 29 (12.7) 19 (8.3)
Ra LAM3 (33) Rosario 89 40 (44.9) 28 (31.5) 2 (2.2) 10 (11.2) 17 (19.1) 16 (18.0) 14 (15.7)
Rb Tuscany
(159) Buenos Aries, Rosario 38 11 (28.9) 22 (57.9) 0 (0.0) 1 (2.6) 0 (0.0) 13‡ (34.2) 6 (15.8)
Pr LAM9 (42) Buenos Aries 26 10 (38.5) 10 (38.5) 0 (0.0) 2 (7.7) 15 (57.7) 5 (19.2) 2 (7.7)
At T1 (53) Atlantic Coast 21 9 (42.9) 7 (33.3) 1 (4.8) 3 (14.3) 2 (9.5) 7 (33.3) 2 (9.5)
Ob LAM5 (725) Buenos Aries 18 7 (38.9) 4 (22.2) 0 (0.0) 2 (11.1) 3 (16.7) 5 (27.8) 2 (11.1)
Os LAM5 (93) Salta 18 7 (38.9) 6 (33.3) 0 (0.0) 3 (16.7) 1 (5.6) 9 (50.0) 2 (11.1)

*Sum does not equal total because of patients with more than one risk factor. Buenos Aires includes the city and surroundings. MDR, multidrug-resistant; TB, tuberculosis; SIT, Shared International Spoligo Type according to Brudey et al. (13); HCW, health care workers.
†Previous hospitalization(s) or concomitant condition.
‡Ten of these case-patients shared a single residence with transvestite sex workers.

Main Article

References
  1. de Kantor  IN, Ritacco  V, Barrera  L. Is multidrug-resistant tuberculosis an emergent infection in Buenos Aires? [in Spanish]. Medicina (B Aires). 1996;56:102–4.PubMedGoogle Scholar
  2. Ritacco  V, Reniero  A, Ambroggi  M, Barrera  LB, López  B, Di Lonardo  M, Inter-hospital spread of multidrug-resistant tuberculosis in Buenos Aires, Argentina. Tuber Lung Dis. 1996;77(Suppl 2):63.
  3. Morcillo  N, Alito  A, Romano  MI, Cataldi  A, Dolmann  A, Reniero  A, Multidrug resistant tuberculosis outbreak in Buenos Aires. DNA fingerprinting analysis of isolates. Medicina (B Aires). 1996;56:45–7.PubMedGoogle Scholar
  4. Ritacco  V, Di Lonardo  M, Reniero  A, Ambroggi  M, Barrera  L, Dambrosi  A, Nosocomial spread of Human Immunodeficiency Virus-related multidrug-resistant tuberculosis in Buenos Aires. J Infect Dis. 1997;176:637–42. DOIPubMedGoogle Scholar
  5. Poggio  G, Togneri  A, Reniero  A, Insúa  A, Guerra  R, Dinerstein  E, AIDS-related multidrug resistant tuberculosis “M” strain spreads within two hospitals in Buenos Aires suburbs. Int J Tuberc Lung Dis. 1997;1(Supp1):523.PubMedGoogle Scholar
  6. Palmero  D, Ritacco  V, Ambroggi  M, Marcela  N, Barrera  L, Capone  L, Multidrug-resistant tuberculosis in HIV-negative patients, Buenos Aires, Argentina. Emerg Infect Dis. 2003;9:965–9. DOIPubMedGoogle Scholar
  7. Aita  J, Barrera  L, Reniero  A, López  B, Biglione  J, Weisburd  G, Hospital transmission of multidrug-resistant Mycobacterium tuberculosis in Rosario, Argentina. Medicina (B Aires). 1996;56:48–50.PubMedGoogle Scholar
  8. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. WHO/HTM/TB/2009.442. Geneva: The Organization; 2009.
  9. World Health Organization. Policy guidance on TB drug susceptibility testing (DST) of second-line drugs. WHO/HTM/TB/2008.392. Geneva: The Organization; 2008.
  10. van Embden  JDA, Cave  MD, Crawford  JT, Dale  JW, Eisenach  KD, Gicquel  B, Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol. 1993;31:406–9.PubMedGoogle Scholar
  11. Kamerbeek  J, Schouls  L, Kolk  A, van Agterveld  M, van Soolingen  D, Kuijper  S, Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol. 1997;35:907–14.PubMedGoogle Scholar
  12. Heersma  HF, Kremer  K, van Embden  J. Computer analysis of IS6110 RFLP patterns of Mycobacterium tuberculosis. Methods Mol Biol. 1998;101:395–422.PubMedGoogle Scholar
  13. Brudey  K, Driscoll  JR, Rigouts  L, Prodinger  WM, Gori  A, Al-Hajoj  SA, Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol. 2006;6:23. DOIPubMedGoogle Scholar
  14. Abadia  E, Zhang  J, dos Vultos  T, Ritacco  V, Kremer  K, Aktas  E, Resolving lineage assignation on Mycobacterium tuberculosis clinical isolates classified by spoligotyping with a new high-throughput 3R SNPs based method. Infect Genet Evol. 2010;10:1066–74. DOIPubMedGoogle Scholar
  15. Palmero  D, Ritacco  V, Ruano  S, Ambroggi  M, Cusmano  L, Romano  M, Multidrug-resistant tuberculosis outbreak in transvestite sex workers, Buenos Aires, Argentina. Int J Tuberc Lung Dis. 2005;9:1168–70.PubMedGoogle Scholar
  16. Pando  MA, De Salvo  C, Bautista  CT, Eyzaguirre  L, Carrion  G, Feola  M, Human immunodeficiency virus and tuberculosis in Argentina: prevalence, genotypes and risk factors. J Med Microbiol. 2008;57:190–7. DOIPubMedGoogle Scholar
  17. Ritacco  V, Morgado  M, Garcia  LF. The situation of HIV/M. tuberculosis in South America. Open Infect Dis J. 2011, 5, (Suppl 1–M7) 81–88 [cited May 20, 2012]. http://benthamscience.com/open/toidj/articles/V005/SI0013TOIDJ/81TOIDJ.htm
  18. Waisman  JL, Palmero  DJ, Güemes-Gurtubay  JL, Videla  JJ, Moretti  B, Cantero  M, Evaluation of the control measures adopted against an epidemic of AIDS-related multidrug-resistant tuberculosis in a Latin-American hospital [in Spanish]. Enferm Infecc Microbiol Clin. 2006;24:71–6. DOIPubMedGoogle Scholar
  19. Gonzalo  X, Ambroggi  M, Cordova  E, Brown  T, Poggi  S, Drobniewski  F. Molecular epidemiology of Mycobacterium tuberculosis, Buenos Aires, Argentina. Emerg Infect Dis. 2011;17:528–31. DOIPubMedGoogle Scholar
  20. Candia  N, Lopez  B, Zozio  T, Carrivale  M, Diaz  C, Russomando  G, First insight into Mycobacterium tuberculosis genetic diversity in Paraguay. BMC Microbiol. 2007;7:75. DOIPubMedGoogle Scholar
  21. Aristimuño  L, Armengol  R, Cebollada  A, España  M, Guilarte  A, Lafoz  C, Molecular characterisation of Mycobacterium tuberculosis isolates in the First National Survey of Anti-Tuberculosis Drug Resistance from Venezuela. BMC Microbiol. 2006;6:90. DOIPubMedGoogle Scholar
  22. Lazzarini  LC, Huard  RC, Boechat  NL, Gomes  HM, Oelemann  MC, Kurepina  N, Discovery of a novel Mycobacterium tuberculosis lineage that is a major cause of tuberculosis in Rio de Janeiro, Brazil. J Clin Microbiol. 2007;45:3891–902. DOIPubMedGoogle Scholar
  23. Ritacco  V, Iglesias  MJ, Ferrazoli  L, Monteserin  J, Dalla Costa  ER, Cebollada  A, Conspicuous multidrug-resistant Mycobacterium tuberculosis cluster strains do not trespass country borders in Latin America and Spain. Infect Genet Evol. 2012;12:711–7. DOIPubMedGoogle Scholar
  24. Burgos  MV, Méndez  JC, Ribon  W. Molecular epidemiology of tuberculosis: methodology and applications. Biomedica. 2004;24(Supp1):188–201.PubMedGoogle Scholar
  25. Gagneux  S, DeRiemer  K, Van  T, Kato-Maeda  M, de Jong  BC, Narayanan  S, Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2006;103:2869–73. DOIPubMedGoogle Scholar
  26. Palmero  D, Ritacco  V, Ambroggi  M, Poggi  S, Güemes Gurtubay  J, Alberti  F, Multidrug-resistant tuberculosis in AIDS patients at the beginning of the millennium. Medicina (B Aires). 2006;66:399–404.PubMedGoogle Scholar
  27. Gagneux  S, Long  CD, Small  PM, Van  T, Schoolnik  GK, Bohannan  BJM. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science. 2006;312:1944–6. DOIPubMedGoogle Scholar
  28. Luciani  F, Sisson  SA, Jiang  H, Francis  AR, Tanaka  MM. The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2009;106:14711–5. DOIPubMedGoogle Scholar
  29. O’Sullivan  DM, McHugh  TD, Gillespie  SH. Mapping the fitness of Mycobacterium tuberculosis strains: a complex picture. J Med Microbiol. 2010;59:1533–5. DOIPubMedGoogle Scholar
  30. Comas  I, Borrell  S, Roetzer  A, Rose  G, Malla  B, Kato-Maeda  M, Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet. 2011;44:106–10. DOIPubMedGoogle Scholar

Main Article

1Additional members of the National TB Laboratory Network who contributed data are listed at the end of this article.

Page created: October 16, 2012
Page updated: October 16, 2012
Page reviewed: October 16, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external